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Abstract
Escherichia coli strains are widely used in academic research and biotechnology. New 
technologies for quantifying strain-specific differences and their underlying contributing factors 
promise greater understanding of how these differences significantly impact physiology, synthetic 
biology, metabolic engineering, and process design. Here, we quantified strain-specific differences 
in seven widely used strains of E. coli (BL21, C, Crooks, DH5a, K-12 MG1655, K-12 W3110, and 
W) using genomics, phenomics, transcriptomics, and genome-scale modelling. Metabolic 
physiology and gene expression varied widely with downstream implications for productivity, 
product yield, and titre. These differences could be linked to differential regulatory structure. 
Analysing high-flux reactions and expression of encoding genes resulted in a correlated and 
quantitative link between these sets, with strain-specific caveats. Integrated modelling revealed 
that certain strains are better suited to produce given compounds or express desired constructs 
considering native expression states of pathways that enable high-production phenotypes. This 
study yields a framework for quantitatively comparing strains in a species with implications for 
strain selection.
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Introduction
Escherichia coli are widely used as a model prokaryote for physiology studies. Some strains 
are important pathogens and others are key host strains for metabolic engineering and 
synthetic biology. This diversity in lifestyle and application reflects the high level of genetic 
diversity within the species. Thanks to the genomics revolution in microbiology that has 
enabled sequencing of diverse strains for any species, it is now known that the genomes of 
different strains of E. coli range in size from 4.5 to over 5.5 Mbp, and the species has a pan-
genome composed of more than 15,000 unique proteins (Lukjancenko et al., 2010, 
Gordienko et al., 2013). Part of this large pan-genome consists of unique metabolic 
capabilities that have been shown to have important implications for infectious disease 
studies and pathogenic niches (Monk et al., 2013, Baumler et al., 2011, Vieira et al., 2011). 
This metabolic diversity is likely to be equally impactful on synthetic biology applications 
(Lee and Kim, 2015). The massive genomic diversity of the E. coli species provides a deep 
pool of strains to use for basic research and for metabolic engineering and synthetic biology 
applications. It also raises an important question: what range of phenotypic behaviours exist 
and how can these be leveraged to further exploit E. coli as a model organism and host 
strain?
A review of industrial biotechnology publications and patents that use E. coli as a host strain 
yielded seven representative E. coli strains that are used often and are good candidates for 
detailed study: the K-12 strains MG1655, W3110, and DH5a, as well as strains BL21, C, 
Crooks, and W (Figure 1A). These strains all have genetic tools available – a required factor 
when choosing a strain for metabolic engineering. The selection of both closely related 
strains (K-12 strains) and more distantly related strains also allowed an examination of 
whether close genetic relatedness is a useful predictor of physiological relatedness and 
production potential. The existing body of work evaluating different E. coli strains in 
metabolic engineering and synthetic biology (Archer et al., 2011, Arifin et al., 2014, Yoon et 
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al., 2012, Vijayendran et al., 2007, Marisch et al., 2013, Chae et al., 2010) demonstrated a 
need for the comprehensive analysis of strain-specific differences. Despite significant 
success in engineering E. coli for industrial production of chemicals and proteins (Lee et al., 
2012b, Kim et al., 2015), there is no unified fundamental basis for selection of one strain 
over another for a given metabolic engineering project or expression of a given construct. 
Previous studies have shown that the choice of host strain for production of a given 
compound has a significant impact on results (Na et al., 2013, Kim et al., 2014) and up until 
now represented a major brute force screening effort. Thus, an important question remains to 
be addressed: what strain of E. coli is best suited for production of a desired product?
Here, a comprehensive comparison incorporating transcriptomics, genomics, and phenomics 
with genome-scale modelling of seven common E. coli production strains is presented and a 
mechanistic basis for the selection of a given E. coli strain for production of particular 
compound is established. The data and models are further used to develop a general strategy 
for synthetic biology host strain selection that can be applied to any production organism 
with sufficient genetic diversity. The work presented here establishes a workflow (Figure S1) 
and represents a resource for similar efforts with other organisms and/or additional omics 
data types.
Results
Whole-genome sequencing and comparative analysis
Seven strains of E. coli were sequenced to comprehensively compare and examine their 
strain-specific genetic differences (Accession numbers and identified differences are 
available in Table S1, Data S1). Accurate genome sequences were determined to be essential 
due to recent studies that demonstrate several differences between the reference sequence of 
E. coli K-12 MG1655 and the stock strains of laboratory E. coli available from culture 
collections (Freddolino et al., 2012). These differences were shown to have substantial 
physiological effects that could confound experimental results and have downstream impacts 
on bioprocess design (Nahku et al., 2011). One of the widely used E. coli strains, C, had no 
public genome sequence available, thus whole genome sequencing was performed to 
establish the genetic parts list for this strain (STAR Methods). The E. coli C draft genome 
was predicted to be 4.54 Mbp in size and has 4,424 open reading frames.
The whole genome sequences of the seven strains were then used to classify the strains 
based on their genetic content. First, a classical MLST scheme (Jaureguy et al., 2008) was 
used to assign the E. coli strains to phylogroups (Figure S2). All strains were assigned to 
group A except for E. coli W that was assigned to group B1. All seven strains are generally 
regarded as safe and non-pathogenic. A full genome alignment and comparison of conserved 
proteins was also performed (STAR Methods). A total of 6,626 unique protein-coding 
sequences were discovered across all seven genomes. Of these, 3,316 genes were shared 
between all seven strains, forming a “core” genome. Of the non-core genes, 1,493 were 
present in 2 to 6 of the strains and 1,817 of the genes were unique to a single strain alone 
(Figure 1C, Data S1). A full-genome DNA alignment showed that the E. coli K-12 strains, 
MG1655, W3110, and DH5a were all part of the same clade. E. coli BL21 and C were also 
part of a similar clade, and E. coli Crooks and W strains were separate from the others with 
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E. coli W being the most distantly related strain (Figure 1B). A full analysis of amino acid 
differences in shared coding sequences between E. coli K-12 MG1655 and each of the other 
strains was performed (Data S1). Such differences may have effects on protein activities 
including catalytic activity, protein folding, and translation efficiency.
Phenotypic characterization of host strains highlights physiological differences
To assess growth dynamics and by-product secretion rates, phenotypic characterizations 
were performed in aerobic and anaerobic M9 minimal media (STAR Methods). Major 
differences were observed between the strains during exponential growth phase. Aerobically, 
the growth rates ranged from 0.61 h−1 (W3110) to 0.97 h−1 (W), with a mean growth rate of 
0.80 ± 0.12 h−1, see Table 1. Anaerobically, DH5a grew slowest (0.18 h−1) and W grew 
fastest (0.90 h−1), with a mean growth rate of 0.53 ± 0.25 h−1. These differences are stark 
given that the strains share more than 95% of genes in central metabolism at greater than 
95% amino acid identity (STAR Methods) indicating vastly different utilization of similar 
central metabolic genetic content. It is also worth highlighting that some strains, such as W, 
could grow nearly as fast anaerobically as they did aerobically through a major increase 
(2.7×) in glucose uptake rate.
While the overall biomass and by-product yields between strains were similar, the strains 
exhibited different organic acid secretion profiles. In aerobic conditions, four of the strains, 
C, DH5a, MG1655, and W3110 exhibited acetate overflow metabolism in this well-aerated 
experiment (Figure 1D), in agreement with past studies (Archer et al., 2011, Marisch et al., 
2013). Anaerobically, all strains exhibited common mixed acid fermentation with production 
of acetate, formate, ethanol, and succinate. Only two strains, the slowest growers, 
BL21(DE3) and DH5a, produced lactate anaerobically (Figure 1E). This physiological 
characterization clearly shows that strains differ in their propensity to make certain 
molecules, e.g., lactate, an industrially relevant, biologically produced chemical, when 
growing in their wild-type state (Jang et al., 2012). The rate of substrate consumption in the 
different strains (Table 1, Figure S3) also exhibited significant variation (a 1.9 and 3.6 fold 
difference aerobically and anaerobically, respectively), a fact that has important implications 
for productivity and bioprocessing costs.
Strain-specific genome-scale models (GEMs) of metabolism reveal differences in 
metabolic capabilities
The large physiological differences across the selected E. coli strains motivated the 
construction of seven strain-specific GEMs (Data S1 and S2) that were used to integrate, 
model, and contextualize the measured physiological data. The models were first validated 
by demonstrating that they could recapitulate a functional flux state by setting the measured 
physiological data (i.e., inputs and outputs – glucose uptake rate, growth rate and by-product 
production rates – See Figure S9). All models passed this test, indicating consistency 
between the models and physiological data. Next, each model’s metabolic content was 
compared to classify reactions as part of “core” or “pan” metabolic capabilities. The core 
content (reactions present in all seven strains) consisted of 1,265 genes, catalysing 2,315 
reactions that utilize 1,776 different metabolites. The total content, present in at least one 
strain, but not shared among all, consisted of 2,526 reactions – indicating that 211 reactions 
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were variably present in different strains. The average model had 2,425 +/− 17 reactions. In 
a recent study of 55 strains of E. coli (Monk et al., 2013) including pathogens and 
environmental isolates, the average model had 2,337 +/− 52 reactions, indicating that there 
was more diverse metabolic content among the 55 strains than exists between the seven 
industrially useful strains examined here. However, several of the differences between the 
seven strains are present in subsystems important for metabolic engineering, including the 
pentose phosphate pathway and amino acid biosynthesis. For this reason, strain-specific 
GEMs of metabolism were used to examine maximum theoretical yield of growth precursors 
and industrial chemicals to explore the functional differences and metabolic capabilities of 
each strain.
Strain-specific metabolic models highlight differences in theoretical yields of industrially 
relevant compounds
The theoretical yields of industrially relevant native and non-native compounds were 
examined by utilizing strain-specific models. A total of 245 heterologous pathways for the 
production of non-native compounds (Campodonico et al., 2014) were integrated with each 
strain-specific model to compare theoretical yields. The yields were calculated using glucose 
as the sole carbon source in both aerobic and anaerobic conditions (Data S4). Overall, the 
majority of the maximum theoretical yields were similar across strains. However, several 
differences were identified between the seven strains. For example, the model of E. coli 
BL21 is unable to produce acrylic acid from heterologous pathways 23 and 24 (Data S4, 
Heterologous aerobic and anaerobic tabs) because it lacks N-acetylglucosamine kinase. 
Likewise, DH5a cannot make 3-hydroxypentanoic acid via a predicted heterologous route 
(pathway 223) due to the lack of homocysteine S-methyltransferase encoded for by mmuM 
(Song et al., 2015). A histogram of differential yield by pathway in each strain is given in 
Figure S4.
All seven strains have theoretical yields greater than 95% of the highest yield predicted for 
any of the strains in most of the 245 pathways. However, 582 (~17%) of the 3,340 
combinations of 7 strains, 245 pathways, and 2 conditions have theoretical yields less than 
95% of the highest yield predicted for any strain in a pathway. Strain W was alone or tied for 
the highest predicted yield in the most aerobic (218) and anaerobic (194) pathways; BL21 
(76 and 41) and C (92 and 40) equalled the highest yield in the fewest pathways. A 
histogram of the 341 combinations of strain and condition that have predicted yields of 45–
95% of the highest yield in the 245 pathways are given in Figure S4 and Data S4; another 
240 combinations are predicted to yield no product. Strain BL21 had minor reductions in 
production yields of all compounds in aerobic conditions due to the lack of 6-
phosphogluconolactonase (PGL) reaction activity (Meier et al., 2012) in the oxidative 
pentose phosphate pathway (PPP), encoded by the gene pgl. This requires an alternate 
pathway for production of ribulose-5-phosphate that does not generate NADPH, one of the 
primary purposes of the oxidative PPP (Fan et al., 2014) (Figure S5).
Analysis using strain-specific models revealed several increased maximum theoretical yield 
advantages. E. coli Crooks and W had a 4–12% greater yield of 2-oxobutanoate on five of 
the different heterologous pathways in anaerobic conditions because of an alternate 
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isoleucine biosynthesis pathway (STAR Methods). Furthermore, models of BL21 and 
Crooks had 21% higher yield of 1,4-butanediol in anaerobic conditions for two of the 
heterologous pathways (i.e., pathways 176 and 177) due to the ornithine aminotransferase 
reaction (STAR Methods). These differences in maximum theoretical yields demonstrate 
that major differences in strain behavior exist based solely on internal reaction content and 
the unique metabolic network structure of each strain. Next, to gain a deeper understanding 
of strain specific behavior, the measured physiological data was integrated with each strain-
specific model.
Integration of phenomics with strain specific models classifies shared and strain-specific 
high flux pathways
The analysis of theoretical yields presented above represents the maximum (i.e., ideal) 
capabilities of each strain. In vivo wild-type strain-specific behaviour can be analysed by 
integrating the measured strain-specific physiological data with its corresponding model. 
The constraint-based modelling techniques of flux variability analysis (FVA) (Mahadevan 
and Schilling, 2003) and Monte Carlo Markov Chain (MCMC) sampling (Schellenberger 
and Palsson, 2009) were performed to determine minimum, maximum, and likely flux 
through each reaction in each strain based on the imposed physiological constraints (for 
example E. coli C, Figure 2A, Figure S9). The resulting probable flux distributions were 
used to classify reactions that must carry high flux (STAR Methods) to achieve the measured 
physiological secretion and growth rates, and were compared in both aerobic (Figure 2B) 
and anaerobic (Figure 2C) conditions.
High flux reactions were compared across the different strains (Figure 2D). Aerobically, 
there were 62 reactions classified as high flux in at least one strain. Of these, 37 were shared 
among all seven strains. Most of the shared reactions were involved in glycolysis, the TCA 
cycle, and the PPP (Data S5). In addition, reactions involved in glutamate metabolism were 
classified as high flux across all seven strains. The remaining 25 reactions were classified as 
high flux in at least one strain, but not shared by all. Some of these differences were obvious 
on a genetic level – for instance, five reactions in the oxidative PPP were classified as high 
flux in all strains except BL21, because, as discussed above, BL21 lacks the pgl gene, 
disabling flux through the oxidative PPP in this strain. Other differences in high flux 
reactions were related to differences in physiological behaviour. For example, acetaldehyde 
dehydrogenase was only a high flux reaction in two strains (DH5a and MG1655 – two of the 
strains that exhibited acetate overflow metabolism). Acetate secretion negatively correlated 
with flux through TCA cycle reactions, including citrate synthase (CS), aconitase 
(ACONTa/b), and isocitrate dehydrogenase (ICDHyr) (Data S5). Under anaerobic 
conditions, there were a total of 64 high flux reactions classified in at least one strain. Of 
these, 29 reactions shared high flux across all seven strains. These included predominantly 
glycolysis reactions and pentose phosphate pathway reactions as well as pyruvate formate 
lyase (PFL).
Transcriptome analysis classifies shared and strain-specific gene expression profiles
To delve deeper into strain-specific behaviour and the observed genetic and physiological 
differences, RNA-seq was used to collect genome-wide transcriptomic profiles of each strain 
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at exponential phase in aerobic and anaerobic conditions (Data S6). Pairwise differential 
expression was compared between each of the seven strains and correlation coefficients were 
calculated to quantify the level of similarity between full expression profiles of shared genes 
for the different strains (Figure 3A and B). A Principal Component Analysis (PCA) was also 
performed that focused on metabolic genes (Figure 3C and D). The analysis highlights 
major differences in expression states. For example, BL21 displayed significantly different 
expression profiles in anaerobic conditions due to high expression of TCA cycle genes. This 
difference is most likely due to a nonsense mutation in the gene encoding the global oxygen-
responsive transcriptional regulator FNR (Pinske et al., 2011) making this strain’s gene 
expression behave more similarly to an aerobic state. Further differences are discussed in the 
STAR Methods Section: Transcriptome analysis classifies shared and strain-specific gene 
expression profiles.
As with reaction flux, gene expression values were analysed for each growth condition and 
classified into highly expressed gene sets (STAR Methods). This analysis identified a group 
of genes that were highly expressed species-wide. In aerobic conditions, 199 metabolic 
genes were classified as highly expressed in at least one of the seven strains (Figure S6, Data 
S5), but only 16 of these genes were significantly highly expressed across all strains. Three 
of these were involved in glycolysis: enolase (eno), fructose-bisphosphate aldolase (fbaA), 
and glyceraldehyde-3-phosphate dehydrogenase (gapA). In anaerobic conditions, 174 
metabolic genes were classified as highly expressed in at least one of the strains, and 23 of 
the genes were highly expressed in all seven strains including eno and fbaA as well as 
acetaldehyde dehydrogenase (adhE) and methionine adenosyltransferase (metK).
Transcription factors involved in differential regulation illuminate distinct regulatory 
strategies
The major differences observed in transcription profiles demonstrate unique regulatory 
mechanisms between strains. Knowledge of transcriptional control is directly applicable to 
bioprocessing and synthetic biology applications for tuning gene expression levels. Most 
transcription factors (TFs) have been characterized in E. coli K-12 MG1655, thus gene 
expression profiles between this strain and the other six were compared in both aerobic and 
anaerobic conditions. An enrichment analysis of TFs known to regulate gene expression was 
performed (STAR Methods). There are 196 TFs with known regulons available in Regulon 
DB (Huerta et al., 1998). For each strain, an average of 28±3 TFs were enriched for 
differential control of expressed genes in aerobic conditions and 29±6 TFs were enriched in 
anaerobic conditions (Data S6). An informative example is that of the galactitol regulon 
which includes gatYZABCD and is negatively repressed by the gatR TF (Nobelmann and 
Lengeler, 1995). The gatR TF is highly enriched for differential expression in all of the 
strains except W3110. In MG1655 and W3110, the gatR gene is inactivated by an IS3E 
insertion leading to constitutive expression of these genes (Nobelmann and Lengeler, 1996). 
This aberrant regulation leads to expression and translation of gat genes that are ultimately 
responsible for nearly 1% of the wild-type E. coli K-12 MG1655 proteome (Li et al., 2014). 
In the other strains, gat gene expression is low, in part due to repression by gatR.
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Other TFs that were significantly enriched for differential expression include, in aerobic 
conditions: arcA (anoxic redox control), cra (the catabolite repressor activator), and gadE 
(glutamic acid decarboxylase involved in maintenance of pH homeostasis), and 
anaerobically: fnr (mediates aerobic to anaerobic transistion), IHF (integration host factor, 
responsible for maintaining DNA architecture), and purR (controls purine nucleotide 
biosynthesis). Transcription factors known to control genes in a shift from aerobic to 
anaerobic states were also examined (Table S2). Examining TF enrichment between strains 
identifies unique, strain-specific control mechanisms for different genes, even those that are 
conserved between strains. Further analysis will aid in determining differential regulatory 
mechanisms between strains of E. coli with the ultimate goal of manipulating gene 
expression to enhance metabolic engineering strategies as well as combating additional 
pathogenic members of the species.
Intersection of high flux pathways with highly expressed genes
A quantified correlation between high flux reactions and gene expression is key to 
understanding overall cell physiology and is of great interest to industrial biotechnology as 
overexpression of genes desired to carry high flux is a widely adapted approach to increase 
production of a target molecule (Lee et al., 2012a). In this study, 50±8% of model-
determined high flux reactions also had encoding genes that were highly expressed. This 
overlap occurred significantly more often than random (empirical p-value < 0.001, 
permutation test, STAR Methods, Figure S7). Several genes, such as eno, fbaA, and gapA, 
were consistently high flux and highly expressed in all seven strains (Figure 4A, Data S7). 
Other gene/reaction pairs were less conserved, including those involved in amino acid 
metabolism such as ilvD, serC, and aspC, perhaps indicating large differences in amino acid 
use and biosynthesis between each of the strains. While a correlation between high flux 
reactions and gene expression is observed, it is unsurprising that several genes/reactions do 
not correlate as it has demonstrated that gene expression can be a poor indicator of 
enzymatic activity (Machado and Herrgard, 2014).
Prior to determining which strain might be best suited to produce a given target compound, 
an analysis was performed to answer the question of whether GEMs can be used to a priori 
predict changes in gene expression from one state to another. Using physiological data in 
aerobic and anaerobic conditions, fluxes were predicted for a shift from aerobic to anaerobic 
conditions. Overlap between model-predicted changes in reaction fluxes and experimentally 
observed changes in gene expression were analysed. On average, the metabolic models 
correctly predicted major changes in flux during a shift from aerobic to anaerobic conditions 
for 82±8% of the major reaction flux changes (30±12 genes per strain, see Table S3 and S4, 
Data S7). The results of this analysis indicated a level of predictability suitable for de novo 
strain-specific prediction in production strains (examples are given in Figure 4B–C).
Model-driven analysis of production potential
An analysis was performed to determine the strain best suited for the production of a given 
compound as well as expression of a given construct from the set of E. coli strains examined 
in this study. A common metabolic engineering approach is to increase expression of the 
genes in a pathway of interest that lead to a product (Lee et al., 2007, Lee et al., 2012a, Huo 
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et al., 2011). Based on this approach, it was reasoned that strains with natively high 
expression in a pathway of interest are likely better poised to produce a given product, as 
they would require fewer interventions to achieve a production goal. Therefore, genome-
scale modelling was integrated with expression data to determine strains that are inherently 
best poised for production of a given product. Strain-specific models were used to predict 
the optimal flux distribution for production of two different sets of compounds in aerobic 
and anaerobic conditions: 1) all 20 amino acids using native E. coli pathways and 2) 20 non-
native compounds using 245 heterologous pathways (Campodonico et al., 2014) (Data S8). 
Combining predicted fluxes with gene expression values allowed for the generation of a 
relative production potential score (‘R-score’, STAR Methods) that gauges a strain’s 
suitability for producing a given compound (e.g., Figure 5C and 5D).
An integrated analysis using transcriptomic data and genome-scale modelling revealed that 
each of the seven strains may be preferentially suited for production of different target 
metabolites. Strains that most often had an R-score >1 for amino acid production were 
MG1655 and DH5a for aerobic conditions (12/20 and 5/20, respectively) and MG1655 and 
W for anaerobic conditions (7/20 and 3/20, respectively). The targeted product also 
highlighted strain-specific differences. For example, in aerobic amino acid over-production 
(Figure 5A), it was found that E. coli W was predicted to be better at production of pyruvate-
derived amino acids leucine and valine due to a more than two-fold greater expression of 
leuC, leuD, and ilvE compared to the other six strains. Variations in production potential 
were also prevalent across the 245 heterologous pathways examined (corresponding to one 
of 20 different industrial compounds, some targeted products originated from multiple native 
precursors in the cell). Similarly, R-scores >1 were distributed across all seven strains 
examined. K-12 MG1655 had the highest number of R-scores >1 for 94 pathways 
aerobically, and W and C had 42 and 41 under anaerobic conditions, respectively (Figure 
5B).
Grouping the 20 different targeted heterologous products leads to a further characterization 
based on which strains were best suited for production of a particular class of compound. 
For example, strain W was best suited for production of 5/20 compounds (2-methyl-1-
butanol, 1-butanol, 3-methyl-1-butanol, 2-keto-isovaleric acid, and 2,3-butanediol) 
independent of the heterologous pathway used (Table S5). In contrast, the best production 
strain for 1,4-butanediol varied based on the heterologous pathway used. For example, strain 
K-12 MG1655 had high expression of 2-oxogluterate dehydrogenase encoding genes sucA, 
sucB, and lpd (2-fold greater than expression for strains C, Crooks, DHa, and W3110) that 
produce succinyl-CoA, a branch point for several of the pathways leading to 1,4-butanediol 
production. However, other heterologous pathways leading to production of 1,4-butanediol 
start from 4-aminobutanal and DH5a was predicted to be best suited for these pathways.
Extending the model-driven analysis to selection of host strains (i.e., chassis) for synthetic 
biology applications revealed strain preferences based on amino acid requirements of a given 
construct. Coding sequences of synthetic biology constructs were obtained from the registry 
of standard biological parts (2015) and their amino acid composition was calculated. 
Further, the overall amino acid makeup of the E. coli proteome is stable (Li et al., 2014) and 
this trend holds true for amino acid frequencies across bacteria (Gilis et al., 2001, Hormoz, 
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2013, Latif et al., 2015). Thus, constructs with amino acid compositions that are 
significantly over-represented may require higher demand for a given amino acid if the goal 
is to significantly produce the construct as a large part of the host strain’s proteome. 
Analysing this concept, the R-score analysis for amino acid production capability was 
applied to each construct by comparing the overlap of a strain’s highly expressed amino acid 
biosynthetic pathways (found to be 1–4 amino acid pathways per strain based on the R-
score) with those overrepresented in each construct. This approach led to a prediction of 
which strains may be best at expressing a certain synthetic biology construct considering 
both construct required and total amino acid pathways enriched in a strain (Figure S8). 
Under aerobic conditions, strain DH5a was predicted to be the best producer for the most 
constructs (568/3,983 or 14% of constructs) due to its inherent high expression of the 
biosynthetic pathways for tyrosine (Y) and phenylalanine (F) (amino acids that are often 
small fractions of the proteome) followed by BL21 (473/3,983 or 12% constructs) for 
similar reasons. This result aligns well with the fact that DH5a is often preferred and used in 
cloning applications (Taylor et al., 1993, Song et al., 2015) and BL21 is popular for 
expression of recombinant proteins (Robichon et al., 2011, Marisch et al., 2013).
In summary, this approach emphasized the importance of strain-specific advantages in terms 
of network structure and native expression states that should be considered when choosing a 
host strain or chassis. Full results are provided in Data S8 and S9.
Discussion
This study establishes a workflow to quantitatively compare strains in a species. This 
workflow was used to guide selection of the best host for applied biotechnology and, in 
general, presents a multi-omic resource for the important bacterial species E. coli. The omics 
data generated here addresses a gap in E. coli knowledge for comparing strains of this well-
known species and its strain-specific information for seven industrially important strains 
grown in two well-defined conditions. This unified multi-omics dataset was integrated with 
GEMs to characterize strain-specific and species-wide properties of E. coli by comparing 
metabolic fluxes, gene expression, and differential regulation across the strains. New, 
quantified relationships between these datasets were drawn, along with an evaluation of the 
production potential of the strains based on maximum theoretical production yields and 
strain-specific native expression states. The compendium of data, GEMs, and production 
pathway analyses presented here provide the basis for analysing the overall diversity and 
production capabilities of the seven E. coli strains studied and could further be leveraged for 
additional applications such as antimicrobial strategies in healthcare. Key findings are 
available in Table S6.
A number of important strain-specific and species-wide properties for E. coli were 
identified. The K-12 strains are genetically very similar considering the overall genetic 
diversity of the 7 strains, yet their expression profiles under aerobic conditions showed 
significant variability (Figure 3). Previous studies have shown that W3110 has an amber 
mutation (stop codon) at position 33 in rpoS which is not found in MG1655 (Vijayendran et 
al., 2007). This mutation has been shown to reduce RpoS activity (Subbarayan and Sarkar, 
2004). RpoS is one of the primary global regulators of E. coli’s complex regulatory network. 
Monk et al. Page 10
Cell Syst. Author manuscript; available in PMC 2017 September 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Thus, a small change can have a large effect on cellular expression patterns. This highlights 
the need to better understand and elucidate transcription factor network architecture in even 
closely related strains of E. coli; the data presented here enables such a study.
The phenotypic differences observed between the strains, despite the fact that they have 
largely similar genomes and metabolic reaction networks compared to other sequenced E. 
coli strains (Monk et al., 2013, Baumler et al., 2011, Vieira et al., 2011), were among the 
most striking results from this study. The glucose uptake rates measured for the different 
strains were observed to vary more than 3-fold in anaerobic conditions. If the measured 
wild-type uptake rates can be even partially conserved when generating a bioprocessing 
strain, selection on this criterion alone could have major implications for strain productivity 
and bioprocess titres (Arifin et al., 2014). Also, there are a number of cases where some 
strains have additional or are lacking certain metabolic enzymes. The maximum theoretical 
production analysis presented here (Figure S4) demonstrates that these details are crucial to 
consider when selecting strains for a metabolic engineering project. Further, the pan-genome 
of this set is relatively small compared to all E. coli strains which have been sequenced thus 
far (Gordienko et al., 2013), implying that other strains may have pathways and enzymes 
available to mine for production purposes. Another key result was the identification of a 
50±8% overlap of high-flux reactions with highly expressed genes that is in line with other 
studies (Holm et al., 2010, Ishii et al., 2007). This significant overlap defines an expected 
outcome for such data sets. Failure modes may be unnecessarily expressed for a given 
bioprocess and are therefore targets for expression reduction.
Maximum theoretical production and the native expression state of the cell are important 
considerations when choosing a strain. The case studies presented here show that specific 
strains have unique flux and gene expression patterns that, in turn, may affect the production 
capacity of a compound or construct. The native expression of genes within a pathway of 
interest is not the only factor influencing the generation of a successful production strain. 
For example, E. coli strain DH5a is often used in cloning applications due to an endA1 
mutation that inactivates an intracellular endonuclease (Taylor et al., 1993) and BL21 is well 
established in recombinant protein production due to a lack of the Lon and OmpT proteases 
(Ratelade et al., 2009). Thus, aspects such as transformation efficiency (Liu et al., 2014), 
phage resistance (Furukawa and Mizushima, 1982), product tolerance (Lennen and 
Herrgard, 2014), and other traits must also be considered. Furthermore, maximizing 
theoretical yield does not necessarily lead to increases in titre or productivity. However, the 
workflow presented here, combining GEMs and omics data, could result in significant time 
and cost savings by reducing the number of genetic modifications necessary to develop high-
level production strains or find a host to produce a construct of interest in a sufficiently high 
amount.
The new multi-omics data set provided in this study was generated using consistent and 
defined conditions for multiple strains of a species. Combined with the integrated analysis 
performed here, it will be of great use for industrial, basic biology, and human health 
applications. For example, this data and the R-score method could be applied to examine the 
production of reactive oxygen species across different strains to determine the impact on 
antimicrobial treatment (Brynildsen et al., 2013, Adolfsen and Brynildsen, 2015). This 
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unified and normalized data set allows one to quantitatively compare strains and represents a 
comprehensive compendium of unique strain characteristics. The generation of similar 
datasets integrated with genome-scale modelling will enable rational strain-selection and 
design for metabolic engineering and synthetic biology projects in other common production 
host organisms.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Genetic and physiological differences between seven strains of E. coli
A) The seven industrial relevant E. coli strains selected for this study. This panel establishes 
the colour scheme that will be used to represent strain-specific data on these strains 
throughout the rest of the manuscript, as well as the motility characteristics of each strain. B) 
A phylogenetic tree based on full-genome DNA alignment of the seven strains. C) Total 
protein families in the strains examined. Core genes (red) are those that were present in all 7 
strains, genes present in 2–6 strains are labelled accessory (yellow), and unique genes are 
only present in a single strain (purple). D & E) Physiological behaviour and comparison of 
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the different strain’s carbon yield in aerobic and anaerobic growth conditions. Yields are 
calculated in terms of glucose uptake rates. Carbon dioxide was not measured. Overall, the 
by-product profiles differed across the strains and some anaerobic yields are not fully 
captured in the by-products measured. This is likely due to CO2 evolution from formate 
dehydrogenase.
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Figure 2. Computationally determined high flux reactions from physiological data
A) Each strain-specific model was constrained using measured physiological data. Flux 
variability analysis and sampling were performed on each constrained model. All fluxes 
were normalized to glucose uptake rate and sorted by mean sampled flux value. All graphs 
for each strain and each growth condition are available in Figure S7. The absolute values of 
normalized flux values were log transformed. High flux reactions were determined to be 
those reactions with sampled-flux values greater than 1.5 standard deviations above the 
mean of all sampled flux values. B and C) High flux reactions for each strain were clustered 
and plotted. The counts of high flux reactions for each strain are indicated next to the strain 
name in parentheses. Shared (core) and unique high flux reactions for each strain are shown 
for aerobic and anaerobic conditions. D) Sampled flux values were compared between the 
strains in aerobic and anaerobic conditions to highlight condition- and strain-specific 
behaviour. Reaction abbreviations are given in Data S3.
Monk et al. Page 21
Cell Syst. Author manuscript; available in PMC 2017 September 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Gene expression analysis
A) Example of a comparison of the transcript levels between strains W3110, MG1655, and 
BL21, as well as their correlation coefficient. Strains MG1655 and W3110 have a 0.94 
correlation coefficient for expression of shared genes. In contrast, strain BL21 shows 
divergent gene expression compared to strains MG1655 and W3110 with a much lower 
correlation coefficient of 0.44 and 0.45, respectively. B) The pairwise correlation 
coefficients for each strain in both aerobic (top, green) and anaerobic (bottom, red) 
conditions. C) PCA plot of expression values for shared metabolic gene expression between 
strains aerobically and D) anaerobically. Scale bars represent metabolic subsystems that 
majorly contribute to the given dimension. Abbreviations: TCA: Citric Acid Cycle, APM: 
Arginine and Proline Metabolism, GLC: Glycolysis/Gluconeogenesis, MET: Methionine 
Metabolism, HIS: Histidine Metabolism, OP: Oxidative Phosphorylation, TLM: Threonine 
and Lysine Metabolism, VLI: Valine, Leucine and Isoleucine Metabolism, PYR: Pyruvate 
Metabolism, TTP: Tryptophan, Tyrosine and Phenylalanine Metabolism, AA: Aspartate and 
Alanine Metabolism.
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Figure 4. A comparison of high flux reactions and highly expressed metabolic genes
A) The occurrence of a given gene and the reaction it catalyses falling in the intersection of 
both high flux and highly expressed sets for the seven strains examined. Several pathways 
are enriched in this intersection set (e.g., lower glycolysis). Genes were grouped if they had 
identical counts under aerobic and anaerobic conditions. There were several genes that were 
in this intersection exclusively for aerobic or anaerobic conditions (right side of graph). B & 
C) The measured physiological data was integrated with genome-scale models to predict 
changes in gene expression during a shift from aerobic to anaerobic conditions. Shown are 
two examples for (B) malate dehydrogenase (MDH) and (C) the Electron Transport System. 
A map is shown of the predicted reaction and its neighbours (left) along with the prediction 
of the intracellular flux change between aerobic and anaerobic conditions (middle). The 
actual measured fold change in expression is graphed (right) for comparison with model-
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predicted flux changes (dashed lines indicate a threshold for minimum magnitude and * 
indicates significance for the predicted and measured changes). The example for prediction 
of mdh (B) demonstrates that the model correctly predicts a change in expression; all 7 
models predicted a change in MDH flux that exceeded the minimum threshold and the 
measured expression change of mdh in each strain was large and significant. The nuo genes 
(C) that catalyse the NADH dehydrogenase reaction also demonstrate good model-based 
prediction of expression change.
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Figure 5. Strain-specific production potential
The product potential for targeted metabolites was evaluated based on native gene 
expression for high yield pathways of interest measured using RNAseq and genome-scale 
modelling (see main text and STAR Methods). A) A heat map displaying the relative 
production potentials for all 20 amino acids (left axis) for each strain (bottom axis) in 
aerobic and anaerobic conditions. Red indicates the highest potential and blue the lowest 
(see legend). B) A heat map of the relative production potential for 245 and 200 viable 
heterologous pathways in aerobic (top) and anaerobic (bottom) conditions, respectively. 
Heterologous pathways are clustered (columns) based on the target product (there can be 
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many compounds for a given compound) and some of the most abundant are labelled on the 
bottom axis. The right axis shows a plot of the number of instances where each strain has an 
‘R-score’ (relative production potential score, see STAR Methods) > 1. C) Example 
demonstrating the production potential for histidine biosynthesis. Shown are the final five 
reaction steps and relative expression levels of their catalysing genes for each strain. Strain 
W3110 (pink) has greater gene expression of these his operon genes, making it particularly 
well suited to produce histidine. D) A similar example demonstrating production potential 
for heterologous production of 2-phenylethanol. Here, the last three steps (before the 
heterologous pathway) are shown with their relative native expression levels. This 
heterologous pathway branches from phenylpyruvate (phpyr), an intermediate of tyrosine 
biosynthesis. DH5a has high native expression of these 3 steps along with others in the 
pathway. All metabolite abbreviations are listed in Data S3. The scores for each product and 
contributing expression values and flux profiles are available in Data S15.
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